Qyuns Therapeutics Co., Ltd. Class H (HK:2509) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Qyuns Therapeutics Co., Ltd. has revised its annual caps for CDMO services with Zhongmei Huadong, boosting projected revenues by increasing service fees for the coming years. This move aims to enhance Cellularforce’s cash flow and operational efficiency while meeting the rising demand for drug development services. The updated agreement reflects the company’s strategic focus on capacity utilization and financial growth.
For further insights into HK:2509 stock, check out TipRanks’ Stock Analysis page.